Stay updated with breaking news from Athersys Board. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces changes to its Board of Directors following the Company’s recent 2023 Annual Meeting of Stockholders. Current Director Jane Wasman, JD, has been ap...
Athersys, Inc. , a regenerative medicine company developing MultiStem® for critical care indications, announces changes to its Board of Directors following the Company’s recent 2023 Annual...
Healthcare Executive and Strategy Consultant Brings Considerable Innovation, Commercialization and Entrepreneurial Expertise ...
Athersys Announces Board of Directors Slate for 2022 Annual Meeting of Stockholders and Director Departures - read this article along with other careers information, tips and advice on BioSpace
Annual Meeting of Stockholders rescheduled to Thursday, July 28, 2022, 8:30 a.m. ETCLEVELAND--(BUSINESS WIRE)--$ATHX--Athersys, Inc. (Nasdaq: ATHX) today announced the postponement of its Annual Meeting of Stockholders, initially scheduled for Wednesday, June 15, 2022, at 8:30 a.m. ET. The Annual Meeting is now sche...